IAS
ZYNE

INR Advisory Services’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

INR Advisory Services’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$3K Hold
477
– – ﹤0.01% 56
2018
Q4 		$1K Buy
+477
New +$2.61K ﹤0.01% 74

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
PP
PDT Partners New York $1.9B AUM 71.86% 1-Year Est. Return

INR Advisory Services's ZYNE Position: Q1 2019 in Review

INR Advisory Services held its Zynerba Pharmaceuticals, Inc (ZYNE) position steady in Q1 2019 at 477 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #56.

INR Advisory Services first reported a position in ZYNE in Q4 2018 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold ZYNE as of Q1 2019.

  • INR Advisory Services held 477 shares of Zynerba Pharmaceuticals, Inc worth $3K as of Q1 2019.
  • INR Advisory Services left its Zynerba Pharmaceuticals, Inc share count unchanged in Q1 2019.
  • Zynerba Pharmaceuticals, Inc made up ﹤0.01% of INR Advisory Services's portfolio in Q1 2019, its #56 holding.
  • INR Advisory Services first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2018 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2019.

Based on INR Advisory Services's 13F filing for Q1 2019, filed 22 Apr 2019.